BPC-157 Capsule (Delayed Release)
ProtocolFor protocol designers building BPC-157 Capsule (Delayed Release) into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 500 mcg-1 mg 1x daily am, fasted dose at ~4 hr half-life informs which scheduling pattern fits.
Key Takeaways
Scheduling lens: BPC-157 Capsule (Delayed Release)'s ~4 hr half-life via oral places it in the daily-dosing bucket. Mechanism: Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine. Engages enteric receptors directly, supporting gut barrier integrity and signalling along the vagal gut-brain axis. Schedule design for BPC-157 Capsule (Delayed Release) starts from the pharmacokinetic constraints implied by this mechanism and the published half-life. The subsections below address daily and weekly timing, cycle length and off-period planning, stack scheduling with other compounds, and travel-and-continuity considerations.
Daily and weekly timing
BPC-157 Capsule (Delayed Release) with a ~4 hr half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily AM, fasted, with consistency mattering more than the absolute clock time of any single dose.
Stack scheduling with other compounds
When BPC-157 Capsule (Delayed Release) is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Oral and subcutaneous compounds can be timed independently; the routes do not interact. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.
Cycle length and off-cycle planning
Standard BPC-157 Capsule (Delayed Release) cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Schedule design for BPC-157 Capsule (Delayed Release) in daily timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for BPC-157 Capsule (Delayed Release) in tapered cycles is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For travel considerations scheduling, BPC-157 Capsule (Delayed Release) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for BPC-157 Capsule (Delayed Release) in wash-out starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | Oral | 500 mcg-1 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | Oral | 300 mcg-1 mg | 4–6 weeks initial cycle |
| Protocol focus | Oral | 500 mcg-1 mg | 1x daily AM, fasted |
| Maintenance phase | Oral | 350 mcg-1 mg | Ongoing with periodic pauses |
Dose timing for BPC-157 Capsule (Delayed Release) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
BPC-157 Capsule (Delayed Release) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- BPC-157 Capsule (Delayed Release) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in protocol / scheduling / cycling protocols.
- BPC-157 Capsule (Delayed Release) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in protocol / scheduling / cycling protocols.
- BPC-157 Capsule (Delayed Release) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in protocol / scheduling / cycling protocols.
- BPC-157 Capsule (Delayed Release) + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in protocol / scheduling / cycling protocols.
Same profile as injectable BPC-157. Best taken away from food for absorption.
Lens-specific safety considerations for protocol / scheduling / cycling use of BPC-157 Capsule (Delayed Release): Same profile as injectable BPC-157. Best taken away from food for absorption. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| BPC-157 Capsule (Delayed Release) | Stable gastric pentadecapeptide (oral) | ~4 hr | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Cycle length and off-cycle period?
When to integrate BPC-157 Capsule (Delayed Release) into an existing stack?
Can I shift my schedule with travel?
What if I miss a dose?
Should I cycle BPC-157 Capsule (Delayed Release)?
How long until I see results from BPC-157 Capsule (Delayed Release)?
Start a BPC-157 Capsule (Delayed Release) Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified BPC-157 Capsule (Delayed Release) and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 1419.5 Da
- Sequence length
- 15 aa
- Half-life
- ~4 hr
- WADA
- Banned (2022→)
- FDA
- Unapproved (Research Only)
- Research
- Preclinical + Limited Human
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for BPC-157 Capsule (Delayed Release) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for BPC-157 Capsule (Delayed Release)
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised